Loading chat...
NJ S2875
Bill
Status
Introduced
1/13/2026
Primary Sponsor
Angela Mcknight
Click for details
AI Summary
- Exempts drug manufacturers and wholesale drug distributors from pharmacist licensing requirements when distributing dialysate drugs and devices for home dialysis to patients with end-stage renal disease
- Requires all dialysate drugs and devices to be FDA-approved, held by properly registered manufacturers or distributors, and delivered in original sealed packaging from the manufacturing facility
- Permits delivery only upon receipt of a physician's order, directly to patients, patient designees, or healthcare providers/institutions administering dialysis therapy
- Mandates manufacturers contract with a board-registered consultant pharmacist to conduct weekly quality assurance assessments of home dialysis drug storage and distribution
- Takes effect on the first day of the third month following enactment
Legislative Description
Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.
Commerce
Last Action
Introduced in the Senate, Referred to Senate Commerce Committee
1/13/2026
Committee Referrals
Commerce1/13/2026
Full Bill Text
No bill text available